Scholar Rock Holding Corporation Common Stock
SRRK
$48.30
-5.07%
Scholar Rock Holding Corporation is a biopharmaceutical company focused on developing therapies for rare neuromuscular diseases, including Spinal Muscular Atrophy (SMA), with lead candidate apitegromab. The company occupies a niche position as a clinical-stage innovator targeting the TGF-beta superfamily, specifically myostatin and latent TGF-beta activation pathways. Current investor attention centers on the upcoming regulatory submission for apitegromab in SMA and the early-stage potential of SRK-439, with the stock surging over 50% in the past year amid positive clinical data and analyst optimism.…
SRRK
Scholar Rock Holding Corporation Common Stock
$48.30
Investment Opinion: Should I buy SRRK Today?
Rating: Hold. The thesis is that Scholar Rock offers a binary outcome tied to apitegromab's approval, with the current price already reflecting high expectations. While the potential upside is significant, the risk of failure and extreme valuation warrant caution. The analyst consensus is Overweight/Buy, but the average target price is not provided; however, the wide EPS estimate range implies uncertainty.
Supporting Evidence: The stock trades at a PB of 20.6x, far above the biotech industry average of 4-6x, indicating a premium for pipeline potential. Revenue is zero, but analysts expect $837.5 million in the next fiscal year, implying a forward PS of ~6x if achieved. The company is unprofitable with a trailing PE of -13.4 and negative free cash flow of -$300.6 million TTM. The 1-year price return of +54.4% and 1-month return of +22.8% show strong momentum, but the stock is near its 52-week high, suggesting limited near-term upside without a catalyst.
Risks & Conditions: The biggest risks are FDA non-approval of apitegromab, cash burn requiring dilution, and valuation compression. This Hold would upgrade to Buy if the stock pulls back to $40 or below (20% discount) or if apitegromab receives positive regulatory news. It would downgrade to Sell if the company announces a dilutive offering or if clinical data disappoints. Overall, the stock appears overvalued relative to its fundamentals but fairly valued if apitegromab succeeds; the risk/reward is balanced, hence Hold.
Sign up to view all
SRRK 12-Month Price Forecast
The AI assessment is neutral with medium confidence. The stock's extreme valuation (PB 20.6x) and binary regulatory catalyst create a balanced risk/reward. The wide range of analyst estimates reflects high uncertainty. The base case of approval with moderate uptake is most likely (45% probability), but the bull case (30%) and bear case (25%) are both plausible. The stance would upgrade to bullish if the stock pulls back to $40 or if positive regulatory news emerges, and downgrade to bearish if cash burn accelerates or clinical data disappoints.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Scholar Rock Holding Corporation Common Stock's 12-month outlook, with a consensus price target around $59.31 and implied upside of +22.8% versus the current price.
Average Target
$59.31
0 analysts
Implied Upside
+22.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$48 - $70
Analyst target range
Six analysts cover Scholar Rock, with a consensus leaning bullish: all recent ratings are Overweight/Buy/Outperform. The average estimated EPS for the next fiscal year is $1.38, with a low of $0.67 and high of $2.02, implying a wide range of expectations. The average revenue estimate is $837.5 million, with a low of $506.4 million and high of $1.13 billion, reflecting uncertainty about apitegromab's launch trajectory. The implied upside to the average target cannot be calculated without explicit price targets, but the bullish consensus suggests significant upside potential. The target range is wide: EPS estimates vary by 3x, indicating high uncertainty about the timing and magnitude of revenue from apitegromab. The high end assumes rapid adoption and peak sales, while the low end reflects potential delays or competitive pressures. Recent ratings from JP Morgan, Piper Sandler, and others have been reaffirmed as Overweight/Buy, with no downgrades, signaling continued confidence. The wide spread in estimates suggests that while the consensus is positive, there is considerable risk, and the stock may experience high volatility around clinical and regulatory milestones.
Bulls vs Bears: SRRK Investment Factors
Scholar Rock presents a high-risk, high-reward opportunity. The bull case hinges on apitegromab's approval and commercial success, supported by strong price momentum and analyst optimism. However, the bear case is equally compelling: no revenue, widening losses, extreme valuation (PB 20.6x vs industry 4-6x), and a cash runway of only 1-2 years. The single most important tension is whether apitegromab will gain FDA approval and achieve the blockbuster sales implied by the current valuation. If it does, the stock could soar; if not, it could collapse. Currently, the evidence slightly favors the bulls given the positive momentum and analyst consensus, but the risk is substantial.
Bullish
- Apitegromab Approval Catalyst: The upcoming regulatory submission for apitegromab in SMA is a major near-term catalyst. With all 6 analysts rating the stock Overweight/Buy, the consensus reflects high expectations for approval and commercial success, which could drive significant upside from the current $54.88 price.
- Strong Price Momentum: The stock has surged 54.4% over the past year and 22.8% in the last month alone, significantly outperforming the S&P 500. This momentum is supported by positive clinical data and analyst optimism, indicating strong investor conviction.
- Large Addressable Market: Apitegromab targets Spinal Muscular Atrophy, a rare neuromuscular disease with high unmet need. If approved, the drug could achieve peak sales in the billions, as reflected in the average revenue estimate of $837.5 million for the next fiscal year.
- Pipeline Optionality: Beyond apitegromab, the company has SRK-439, an early-stage myostatin inhibitor for rare neuromuscular diseases. This provides additional upside potential and diversifies pipeline risk, though it is still preclinical.
Bearish
- No Revenue and Deep Losses: Scholar Rock has zero revenue and reported a net loss of $90.97 million in Q4 2025, up from $66.45 million a year earlier. The company is burning cash at a rate of $300.6 million TTM free cash flow, raising concerns about financial sustainability.
- Extreme Valuation Premium: The price-to-book ratio of 20.6x is far above the biotech industry average of 4-6x, indicating the stock is priced for perfection. This leaves little room for error; any negative news could trigger a sharp de-rating.
- Regulatory and Clinical Risk: Apitegromab's approval is not guaranteed. The FDA could request additional trials or reject the submission, which would devastate the stock. The wide range of analyst EPS estimates ($0.67 to $2.02) highlights the uncertainty.
- Cash Runway Concerns: With $327.3 million in cash and a quarterly burn rate of ~$90 million, the company has roughly 1-2 years of runway. It will likely need to raise capital through equity offerings, diluting existing shareholders.
SRRK Technical Analysis
The stock is in a strong uptrend, with a 1-year price change of +54.4%, significantly outperforming the S&P 500's +19.1%. Currently trading at $54.88, it sits at 97% of its 52-week range ($27.07-$56.54), indicating the stock is near its highs and reflecting robust momentum. This positioning suggests bullish sentiment but also raises caution about potential overextension, as the stock has rallied sharply from its lows. Short-term momentum is accelerating: the 1-month price change is +22.8% versus the 3-month change of +9.7%, showing a recent pickup in buying pressure. The 1-month relative strength of +24.1% versus the S&P 500 confirms strong near-term outperformance. However, the 3-month relative strength is slightly negative at -3.8%, indicating that the stock lagged the market during the March-May period before the recent surge. Key resistance is at the 52-week high of $56.54; a breakout above this level would signal a continuation of the uptrend and potentially open the door to further gains. Support lies at the 52-week low of $27.07, though the stock is far above that level. The beta of 0.68 indicates the stock is less volatile than the market, which is unusual for a biotech and may reflect its recent steady climb rather than sharp swings.
Beta
0.68
0.68x market volatility
Max Drawdown
-34.9%
Largest decline past year
52-Week Range
$27-$58
Price range past year
Annual Return
+20.8%
Cumulative gain past year
| Period | SRRK Return | S&P 500 |
|---|---|---|
| 1m | -1.8% | +0.4% |
| 3m | +1.7% | +5.5% |
| 6m | +9.1% | +8.4% |
| 1y | +20.8% | +18.9% |
| ytd | +12.9% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SRRK Fundamental Analysis
Scholar Rock is a pre-revenue biotech, with zero revenue reported in the most recent quarter (Q4 2025) and all prior quarters. The company relies on cash reserves and financing to fund operations, with net losses of $90.97 million in Q4 2025, up from $66.45 million in Q4 2024, indicating widening losses as R&D spending increased. The trailing twelve-month free cash flow is -$300.6 million, highlighting significant cash burn. The company is unprofitable, with a net loss of $90.97 million in Q4 2025 and a gross profit of -$0.43 million (negative gross margin due to cost of revenue exceeding zero revenue). Operating expenses were $91.47 million in Q4 2025, driven by R&D of $46.45 million and SG&A of $45.02 million. The net loss has been growing over the past year, from $66.45 million in Q4 2024 to $90.97 million in Q4 2025, reflecting increased investment in clinical trials. Balance sheet health is a key concern: the company has a current ratio of 6.95 and cash of $327.3 million as of Q4 2025, providing a runway of approximately 1-2 years given the current burn rate. Debt-to-equity is 0.44, indicating moderate leverage, but the negative free cash flow and reliance on equity financing (common stock issued of $73.3 million in Q4 2025) raise financial risk. ROE is -154%, reflecting deep losses relative to shareholder equity.
Quarterly Revenue
$0.0B
2025-12
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-300637000.0B
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SRRK Overvalued?
Since net income is negative, the price-to-sales (PS) ratio is not meaningful (zero revenue). The trailing PE is -13.4, and forward PE is -23.2, both negative due to losses. The most relevant metric is the price-to-book (PB) ratio of 20.6, which is extremely high and indicates the market is valuing the company's assets at a significant premium, likely based on pipeline potential rather than tangible book value. The EV/EBITDA of -13.1 is also negative, confirming the lack of earnings. Compared to the biotechnology industry average PB ratio (typically around 4-6x), Scholar Rock's PB of 20.6x represents a substantial premium, reflecting investor optimism about apitegromab's commercial potential. This premium may be justified if the drug receives approval and achieves blockbuster sales, but it also implies high expectations. Historically, the PB ratio has ranged from 0.69 (June 2022) to 20.6 (current), currently at the highest level in the data series. This suggests the stock is priced for perfection, with the market fully discounting successful commercialization. The PEG ratio is -0.40, which is not meaningful due to negative earnings growth.
PE
-13.4x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-13.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Scholar Rock's financial profile is precarious. The company has zero revenue and reported a net loss of $90.97 million in Q4 2025, with TTM free cash flow of -$300.6 million. The cash balance of $327.3 million provides only about 1-2 years of runway at the current burn rate, forcing likely future equity dilution. The debt-to-equity ratio of 0.44 is moderate, but negative ROE of -154% and negative EBITDA underscore the lack of profitability. Any delay in apitegromab's approval could force the company to raise capital at unfavorable terms.
Market & Competitive Risks: The stock's PB ratio of 20.6x is extremely high relative to the biotech industry average of 4-6x, implying the market is pricing in successful commercialization. If apitegromab faces regulatory setbacks or competition from other SMA therapies, the valuation could compress sharply. The beta of 0.68 suggests lower volatility than the market, but this may be misleading given the stock's recent rally; a sector rotation away from biotech or a broad market downturn could still impact the stock. The short ratio of 14.77 days indicates high short interest, reflecting bearish bets that could amplify downside if negative news hits.
Worst-Case Scenario: The most damaging scenario would be a FDA rejection of apitegromab or a clinical failure in ongoing trials. In such an event, the stock could fall to its 52-week low of $27.07, representing a -50.7% decline from the current price of $54.88. The historical max drawdown of -34.86% provides a floor, but a complete loss of pipeline value could push the stock even lower, potentially below $20. Investors could lose more than 50% of their investment in this adverse scenario.
FAQ
The key risks are: 1) Regulatory risk: Apitegromab may not receive FDA approval, which would devastate the stock. 2) Financial risk: The company has no revenue, a net loss of $90.97 million in Q4 2025, and TTM free cash flow of -$300.6 million. With $327.3 million cash, the runway is only 1-2 years, likely requiring dilutive financing. 3) Valuation risk: The PB of 20.6x is extremely high, leaving little margin for error. 4) Competitive risk: Other SMA therapies could limit apitegromab's market share. The most severe risk is FDA rejection, which could lead to a 50%+ decline.
The 12-month forecast is highly uncertain, with three scenarios: Bull case (30% probability) sees apitegromab approval and strong uptake, driving the stock to $65-$80. Base case (45% probability) expects approval with moderate uptake, keeping the stock in a $50-$65 range. Bear case (25% probability) involves regulatory setbacks or clinical failure, sending the stock to $27-$40. The base case is most likely, but the wide range of analyst EPS estimates ($0.67-$2.02) underscores the uncertainty. The stock's near-term direction will depend on FDA news and clinical data.
SRRK appears overvalued based on traditional metrics. The price-to-book ratio of 20.6x is significantly higher than the biotech industry average of 4-6x, indicating the market is paying a substantial premium for pipeline potential. The trailing PE is -13.4 and forward PE is -23.2, both negative due to losses. The EV/EBITDA of -13.1 also reflects lack of earnings. However, if apitegromab achieves the average revenue estimate of $837.5 million, the forward PS would be about 6x, which is reasonable for a high-growth biotech. The valuation implies the market expects successful commercialization and rapid revenue growth. Historically, the PB has ranged from 0.69 to 20.6, currently at the highest level, suggesting the stock is priced for perfection.
SRRK is a high-risk, high-reward stock suitable only for aggressive investors. The stock has surged 54.4% over the past year and trades at a PB of 20.6x, far above the biotech industry average of 4-6x, reflecting high expectations for apitegromab. Analyst consensus is bullish with all 6 analysts rating it Overweight/Buy, but the wide EPS estimate range ($0.67-$2.02) highlights uncertainty. The biggest downside risk is FDA rejection, which could send the stock to its 52-week low of $27.07, a 50.7% decline. For investors with a high risk tolerance and a long-term horizon, it could be a good buy if they believe in apitegromab's approval and commercial success. However, for conservative investors, the risk/reward is unfavorable given the extreme valuation and binary nature.
SRRK is best suited for short-to-medium-term trading given its binary catalyst nature. The stock's beta of 0.68 is lower than the market, but its price is highly sensitive to regulatory and clinical news. The upcoming FDA submission for apitegromab makes the next 12 months critical. Long-term holding is risky because the company's cash burn may require dilution, and the pipeline is narrow. A suggested minimum holding period is 12 months to capture the regulatory decision. For long-term investors, the risk of total loss is significant if apitegromab fails. Short-term traders can capitalize on volatility around news events.